Ontology highlight
ABSTRACT:
SUBMITTER: Sun JM
PROVIDER: S-EPMC3776982 | biostudies-literature | 2013 Sep
REPOSITORIES: biostudies-literature
Sun J M JM Kim J R JR Do I G IG Lee S Y SY Lee J J Choi Y L YL Ahn J S JS Ahn M J MJ Park K K
British journal of cancer 20130820 6
<h4>Background</h4>The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor.<h4>Methods</h4>This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(-2)) once every 3 weeks in previously treated SCLC patients. The primary end point was to determine the maximum tolerated dose of everolimus.<h4>Results</h4>Among 21 enrolled patients, common d ...[more]